ESS1: a pathogenic fungal target for a novel class of broad-spectrum therapeutic agents

Ended Project Grant Awarded Last action

Award ID
R43AI162468
Recipient
Awarding agency
Obligated
$895,590

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Funding
  • $597,060.00 Federal
  • $298,530.00 Non-federal
Place of performance
Union, NJ 07083, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
There is a world-wide need for improved treatment of systemic, life-threatening fungal infections. Current therapies are limited by the small number of approved drugs, toxicities, drug- drug interactions, mode of administration, and growing problems of drug resistance and emerging pathogens. Treatment also suffers from a lack of rapid clinical diagnoses, leading to dependence on broad-spectrum antifungal drugs. Moreover, existing antifungal drug classes target membrane and cell wall integrity, and there is a need to develop drugs against targets with new modes of action. Available evidence suggest ESS1 might be one such target. ESS1 is an essential prolyl isomerase that is highly conserved in fungal pathogens, including candida albicans and aspergillus fumigatus, and its mechanism-of-action is complementary in that IT does not overlap with targets of existing antifungals. Several small molecule "hits" that show chemical-genetic interactions with ESS1 mutant cells have been identified, and fungal ESS1 structure differs sufficiently from its human ortholog (PIN1) to suggest that development of selective ESS1 inhibitors is feasible. The specific aims of this phase i proposal are to (1) validate ESS1 as a druggable target and (2) identify inhibitor scaffolds that are chemically tractable for a "HIT to lead" drug development program. The approach will use biochemical and whole-cell assays to test inhibitors against ESS1 and PIN1 enzymes, fungal pathogens, and mammalian cells, and to develop a robust exploratory chemistry program to accomplish these aims. The outcomes will advance this program into HIT-to-lead, lead optimization and pre-clinical studies (phase II). The long-term objective is to develop ESS1 inhibitors into a new class of broad-spectrum antifungal drugs.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $298,530 $0
Original award $298,530 $298,530

Quick answers

Who received award R43AI162468?

R43AI162468 was awarded to Kathera Bioscience Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 17, 2021.

How much is award R43AI162468 worth?

$895,590 has been obligated on R43AI162468: $597,060 in federal funding and $298,530 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login